{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:57:18Z","timestamp":1788926238578,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["INI-147824"],"award-info":[{"award-number":["INI-147824"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"crossref","award":["TFF 122868"],"award-info":[{"award-number":["TFF 122868"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Cancer Society"},{"DOI":"10.13039\/100012273","name":"Lotte & John Hecht Memorial Foundation","doi-asserted-by":"crossref","award":["703014"],"award-info":[{"award-number":["703014"]}],"id":[{"id":"10.13039\/100012273","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Queen Elizabeth II Graduate Scholarship in Science & Technology"},{"name":"BioCanRx"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ymthe.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T22:15:35Z","timestamp":1508796935000},"page":"56-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds"],"prefix":"10.1016","volume":"26","author":[{"given":"Mohammed","family":"Selman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rousso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan Hee","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader A.","family":"El-Sayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Varette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Le Boeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Tzelepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie C.","family":"Crans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Simon","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.10.014_bib1","doi-asserted-by":"crossref","first-page":"e1003836","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.10.014_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2015.62.5244","article-title":"Oncolytic virus-mediated immunotherapy: a combinatorial approach for cancer treatment","volume":"33","author":"Lawler","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.30813","article-title":"Oncolytic maraba virus MG1 as a treatment for sarcoma","volume":"141","author":"Le Boeuf","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2017.10.014_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/cgt.2013.55","article-title":"Overcoming cancer cell resistance to VSV oncolysis with JAK1\/2 inhibitors","volume":"20","author":"Escobar-Zarate","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2017.10.014_bib7","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/ncomms7410","article-title":"Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing","volume":"6","author":"Arulanandam","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2017.10.014_bib8","doi-asserted-by":"crossref","first-page":"26786","DOI":"10.1038\/srep26786","article-title":"First-in-class small molecule potentiators of cancer virotherapy","volume":"6","author":"Dornan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2017.10.014_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00461-17","article-title":"Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"91","author":"Felt","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib10","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.10.014_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2017.10.014_bib12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.10.014_bib13","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1038\/ncomms14447","article-title":"Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression","volume":"8","author":"Kalkavan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2017.10.014_bib14","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-\u03c3 has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2017.10.014_bib15","doi-asserted-by":"crossref","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2017.10.014_bib16","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2017.10.014_bib17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.10.014_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T\u00a0cell infiltration and improves Anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2017.10.014_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2017.10.014_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/cr020607t","article-title":"The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds","volume":"104","author":"Crans","year":"2004","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ymthe.2017.10.014_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccr.2014.12.012","article-title":"Vanadium\u2013phosphatase complexes: Phosphatase inhibitors favor the trigonal bipyramidal transition state geometries","volume":"301\u2013302","author":"McLauchlan","year":"2015","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ymthe.2017.10.014_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jinorgbio.2008.12.003","article-title":"Vanadium treatment of type 2 diabetes: a view to the future","volume":"103","author":"Thompson","year":"2009","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jinorgbio.2006.08.016","article-title":"Vanadium in diabetes: 100 years from phase 0 to phase I","volume":"100","author":"Thompson","year":"2006","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1040-8428(01)00221-9","article-title":"Vanadium in cancer treatment","volume":"42","author":"Evangelou","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2010.01.030","article-title":"Vanadium in the detection, prevention and treatment of cancer: the in\u00a0vivo evidence","volume":"294","author":"Bishayee","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2017.10.014_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jinorgbio.2015.03.004","article-title":"Thirty years through vanadium chemistry","volume":"147","author":"Costa Pessoa","year":"2015","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jinorgbio.2017.05.010","article-title":"Antitumoral effect of vanadium compounds in malignant melanoma cell lines","volume":"174","author":"Rozzo","year":"2017","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00775-016-1389-0","article-title":"Bis(acetylacetonato)-oxidovanadium(IV) and sodium metavanadate inhibit cell proliferation via ROS-induced sustained MAPK\/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells","volume":"21","author":"Wu","year":"2016","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.canlet.2014.11.039","article-title":"Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine","volume":"357","author":"Clark","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2017.10.014_bib30","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1016\/j.bmc.2016.09.058","article-title":"Inhibition of the metastatic progression of breast and colorectal cancer in\u00a0vitro and in\u00a0vivo in murine model by the oxidovanadium(IV) complex with luteolin","volume":"24","author":"Naso","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biocel.2016.02.015","article-title":"In\u00a0vitro and ex\u00a0vivo vanadium antitumor activity in (TGF-\u03b2)-induced EMT. Synergistic activity with carboplatin and correlation with tumor metastasis in cancer patients","volume":"74","author":"Petanidis","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nri1530","article-title":"Protein tyrosine phosphatases and the immune response","volume":"5","author":"Mustelin","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib33","doi-asserted-by":"crossref","first-page":"10306","DOI":"10.1073\/pnas.89.21.10306","article-title":"Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation","volume":"89","author":"O\u2019Shea","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.10.014_bib34","doi-asserted-by":"crossref","first-page":"4013639","DOI":"10.1155\/2016\/4013639","article-title":"Role of vanadium in cellular and molecular immunology: association with immune-related inflammation and pharmacotoxicology mechanisms","volume":"2016","author":"Tsave","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ymthe.2017.10.014_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/1547691X.2016.1250848","article-title":"Thymic cytoarchitecture changes in mice exposed to vanadium","volume":"14","author":"Ustarroz-Cano","year":"2017","journal-title":"J.\u00a0Immunotoxicol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/02713689009069938","article-title":"Vanadate promotes reactivation and iontophoresis-induced\u00a0ocular shedding of latent HSV-1\u00a0W in different host animals","volume":"9","author":"Gordon","year":"1990","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ymthe.2017.10.014_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1348-0421.1984.tb02948.x","article-title":"Enhancement of Newcastle disease virus-induced fusion of mouse L cells by sodium vanadate","volume":"28","author":"Yamamoto","year":"1984","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2017.10.014_bib39","doi-asserted-by":"crossref","first-page":"e1285992","DOI":"10.1080\/2162402X.2017.1285992","article-title":"Oncolytic measles virus encoding interleukin-12 mediates potent anti-tumor effects through T\u00a0cell activation","volume":"6","author":"Veinalde","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2017.10.014_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JVI.75.2.750-758.2001","article-title":"Herpes simplex virus triggers and then disarms a host antiviral response","volume":"75","author":"Mossman","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","article-title":"The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.014_bib42","first-page":"35","article-title":"The interaction of vanadate with tyrosine kinases and phosphatases","volume":"4","author":"Gresser","year":"1987","journal-title":"Adv. Protein Phosphatases"},{"key":"10.1016\/j.ymthe.2017.10.014_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.onc.1209795","article-title":"Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB","volume":"26","author":"Lallemand","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2017.10.014_bib44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.10.014_bib45","doi-asserted-by":"crossref","first-page":"12759","DOI":"10.1021\/ja00156a013","article-title":"Reaction chemistry of BMOV, bis(maltolato)oxovanadium(IV), a potent insulin mimetic agent","volume":"117","author":"Orvig","year":"1995","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2017.10.014_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/gt.2014.83","article-title":"Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model","volume":"22","author":"Ruotsalainen","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.10.014_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib48","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib49","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ymthe.2017.01.023","article-title":"Inhibitory receptors induced by VSV viroimmunotherapy are not necessarily targets for improving treatment efficacy","volume":"25","author":"Shim","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.014_bib50","doi-asserted-by":"crossref","first-page":"11899","DOI":"10.1021\/acs.joc.5b02229","article-title":"Antidiabetic, chemical, and physical properties of organic vanadates as presumed transition-state inhibitors for phosphatases","volume":"80","author":"Crans","year":"2015","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/qjmed\/hcn003","article-title":"A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus","volume":"101","author":"Smith","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.ymthe.2017.10.014_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.3311","article-title":"The tumor suppressor PTEN has a critical role in antiviral innate immunity","volume":"17","author":"Li","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrm2039","article-title":"Protein tyrosine phosphatases: from genes, to function, to disease","volume":"7","author":"Tonks","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib55","doi-asserted-by":"crossref","first-page":"10177","DOI":"10.1074\/jbc.M110.163295","article-title":"Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer","volume":"286","author":"Wang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib56","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1073\/pnas.94.3.843","volume":"94","author":"He","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.10.014_bib57","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguy\u00ean","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.10.014_bib58","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1073\/pnas.0912344107","article-title":"Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production","volume":"107","author":"Alain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.10.014_bib59","doi-asserted-by":"crossref","first-page":"13547","DOI":"10.1074\/jbc.M007948200","article-title":"Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak\/Stat pathway","volume":"276","author":"Gamero","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib60","doi-asserted-by":"crossref","first-page":"32516","DOI":"10.1074\/jbc.M005366200","article-title":"Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis","volume":"275","author":"Huang","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib61","doi-asserted-by":"crossref","first-page":"C1640","DOI":"10.1152\/ajpcell.1998.275.6.C1640","article-title":"Activation of the JAK-STAT pathway by reactive oxygen species","volume":"275","author":"Simon","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cellsig.2006.09.003","article-title":"STAT1 as a key modulator of cell death","volume":"19","author":"Kim","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ymthe.2017.10.014_bib63","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1074\/jbc.M302637200","article-title":"STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis","volume":"279","author":"Townsend","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.10.014_bib64","first-page":"801","article-title":"Immunotherapy in renal cell carcinoma","volume":"13","author":"Bukowski","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.ymthe.2017.10.014_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2017.01.002","article-title":"Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in\u00a0vitro activities","author":"Levina","year":"2017","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ymthe.2017.10.014_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-61779-340-0_10","article-title":"Propagation, purification, and in\u00a0vivo testing of oncolytic vesicular stomatitis virus strains","volume":"797","author":"Diallo","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.10.014_bib67","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mt.2010.264","article-title":"Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy","volume":"19","author":"Sobol","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.014_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.10.014_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2105-10-48","article-title":"GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists","volume":"10","author":"Eden","year":"2009","journal-title":"BMC Bioinformatics"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617305300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617305300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T21:02:17Z","timestamp":1546462937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617305300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1525001617305300"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.014","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}